Britain Courts Anthropic Amid US Defense Department Dispute 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Jan. 18, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in New York on behalf of certain purchasers of shares of Abeona Therapeutics Inc (NASDAQ:ABEO) over alleged Securities Laws Violations by Abeona Therapeutics Inc.
Investors who purchased shares of Abeona Therapeutics Inc (NASDAQ: ABEO) have certain options and for certain investors there are short and strict deadlines running. Deadline: February 14, 2017. NASDAQ:ABEO investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that the science behind Abeona’s proposed gene therapy treatment for Sanfilippo syndrome is unviable, that Steven H. Rouhandeh, Abeona Therapeutics, Inc’s Executive Chairman and Principal Executive Officer, previously worked in a high ranking position for a biotech promoter who was convicted of securities fraud and involved in manipulating biotech stocks, and that as a result, Defendants’ statements about Abeona Therapeutics, Inc’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Those who purchased Abeona Therapeutics Inc (NASDAQ: ABEO) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
